21st Austria weekly - Valneva Warimpex RHI Magnesita 30/05/2023 [pic1]Valneva: Valneva. an Austrian/French specialty vaccine company today announces the filing of a regulatory application with Health Canada for marketing approval Company’s single-shot chikungunya candidate VLA1553 in persons aged 18 years and above. This is second VLA1553 filed by Company intends to make additional submissions 2023.Valneva: performance: -3.30% Warimpex: The business operations Warimpex Group